Larimar Therapeutics (LRMR) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free LRMR Stock Alerts $7.32 +0.20 (+2.81%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:34 AM | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) to Post FY2026 Earnings of ($2.65) Per Share, William Blair ForecastsMay 10 at 11:12 AM | finance.yahoo.comCompanies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In GrowthMay 10 at 6:12 AM | markets.businessinsider.comBuy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial OutlookMay 10 at 1:12 AM | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA TreatmentMay 9, 2024 | msn.comLarimar Therapeutics files for $300M mixed shelf offeringMay 9, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024May 9, 2024 | washingtonpost.comLarimar: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comLarimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 6, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Up 6%Larimar Therapeutics (NASDAQ:LRMR) Shares Up 6%April 5, 2024 | marketbeat.comEquities Analysts Set Expectations for Larimar Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LRMR)Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Larimar Therapeutics in a report issued on Wednesday, April 3rd. Leerink Partnrs analyst J. Park expects that the company will post earnings of ($0.25) per sApril 4, 2024 | marketbeat.comEquities Analysts Set Expectations for Larimar Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:LRMR)Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 earnings estimates for shares of Larimar Therapeutics in a research report issued on Wednesday, April 3rd. Leerink Partnrs analyst J. Park forecasts that the company will post earniApril 4, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Rating of "Buy" from BrokeragesShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given a consensus recommendation of "Buy" by the five brokerages that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price amonApril 4, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Earns "Outperform" Rating from Leerink PartnrsLeerink Partnrs reiterated an "outperform" rating on shares of Larimar Therapeutics in a report on Wednesday.April 3, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.36Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.36April 3, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Research Coverage Started at SVB LeerinkSVB Leerink began coverage on shares of Larimar Therapeutics in a research note on Wednesday. They issued an "outperform" rating and a $25.00 price objective on the stock.March 28, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Trading 8.1% Higher Larimar Therapeutics (NASDAQ:LRMR) Trading 8.1% HigherMarch 27, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Up 221.6% in MarchLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 1,630,000 shares, an increase of 221.6% from the February 29th total of 506,800 shares. Based on an average trading volume of 570,900 shares, the days-to-cover ratio is currently 2.9 days.March 18, 2024 | marketbeat.comJMP Securities Reiterates Market Outperform Rating for Larimar Therapeutics (NASDAQ:LRMR)JMP Securities reissued a "market outperform" rating and set a $25.00 price objective on shares of Larimar Therapeutics in a research note on Friday.March 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 17, 2024 | marketbeat.comShort Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Drops By 18.0%Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) was the target of a large decrease in short interest in February. As of February 29th, there was short interest totalling 506,800 shares, a decrease of 18.0% from the February 14th total of 618,200 shares. Based on an average daily trading volume, of 478,200 shares, the short-interest ratio is currently 1.1 days.March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspMarch 14, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023March 14, 2024 | sfgate.comLarimar: Q4 Earnings SnapshotMarch 14, 2024 | benzinga.comRecap: Larimar Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comLarimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial ResultsMarch 14, 2024 | globenewswire.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentMarch 12, 2024 | markets.businessinsider.comBuy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s AtaxiaMarch 12, 2024 | msn.com3 Best Stocks to Buy Now, 3/12/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)March 11, 2024 | finance.yahoo.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s AtaxiaMarch 11, 2024 | globenewswire.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's AtaxiaMarch 11, 2024 | msn.comLarimar Therapeutics to Present at Global Biopharma Conference in MiamiMarch 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Purchases 525,000 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Adage Capital Partners GP L.L.C. increased its position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 80.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,176,680 shares of the company's stock after buying anMarch 6, 2024 | globenewswire.comLarimar Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceMarch 4, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Sold by Acadian Asset Management LLCAcadian Asset Management LLC lessened its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 71.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,947 shares of tMarch 3, 2024 | bizjournals.comLocal life sciences companies reeled in more than $750M in stock sales in first two months of 2024February 27, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Trading Down 4.8%Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 4.8%February 23, 2024 | finance.yahoo.comLRMR Mar 2024 17.500 callFebruary 23, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 putFebruary 23, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Rating Reiterated by Lifesci CapitalLifesci Capital reiterated an "outperform" rating on shares of Larimar Therapeutics in a research note on Tuesday.February 23, 2024 | marketbeat.comFY2023 Earnings Estimate for Larimar Therapeutics, Inc. (NASDAQ:LRMR) Issued By Lifesci CapitalLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at Lifesci Capital issued their FY2023 earnings per share estimates for Larimar Therapeutics in a research note issued on Tuesday, February 20th. Lifesci Capital analyst C. Jubinville forecasts that the company will posFebruary 22, 2024 | finance.yahoo.comLRMR Mar 2024 25.000 callFebruary 21, 2024 | markets.businessinsider.comBuy Rating Affirmed: Larimar Therapeutics’ Nomlabofusp Shows Potential in Friedreich’s Ataxia TreatmentFebruary 19, 2024 | msn.comInsider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous PurchaseFebruary 19, 2024 | finance.yahoo.comLRMR Mar 2024 15.000 putFebruary 18, 2024 | msn.comLarimar Therapeutics Raises $172.5 Million in Public Offering to Propel Rare Disease ResearchFebruary 16, 2024 | finance.yahoo.comLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesFebruary 16, 2024 | globenewswire.comLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesFebruary 16, 2024 | marketbeat.comInsider Buying: Larimar Therapeutics, Inc. (NASDAQ:LRMR) Director Buys 4,290,617 Shares of StockLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) Director James E. Flynn acquired 4,290,617 shares of the company's stock in a transaction on Friday, February 16th. The shares were purchased at an average cost of $8.74 per share, with a total value of $37,499,992.58. Following the completion of the acquisition, the director now directly owns 6,151,406 shares in the company, valued at approximately $53,763,288.44. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address [URGENT] DO NOT Touch These AI Stocks! (Ad)Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over? Click here for our #1 AI Stock for 2024 and Beyond LRMR Media Mentions By Week LRMR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LRMR News Sentiment▼0.200.58▲Average Medical News Sentiment LRMR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LRMR Articles This Week▼132▲LRMR Articles Average Week Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verve Therapeutics News Altimmune News KalVista Pharmaceuticals News Travere Therapeutics News Oculis News Shattuck Labs News COMPASS Pathways News Arbutus Biopharma News Adlai Nortye News Astria Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LRMR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
